I-Agent ye-rosuvastatin ye-antilipemic i-Rosuvastatin iphatha i-dyslipidemia

I-Rosuvastatin inqanda i-enzyme ye-hydroxymethylglutaryl-CoA reductase kwisibindi, eyanciphisa i-cholesterol synthesis kunye ne-serum cholesterol kunye namanqanaba e-triglyceride. Ngaphezu koko, i-Rosuvastatin yonyusa isibindi kunye nokuchithwa kwe-low-density lipoprotein cholesterol (LDL-C), ngelixa iphakamisa amanqanaba e-high-density lipoprotein cholesterol (HDL-C). Ukongeza kwimiphumo yokunciphisa i-lipid, i-Rosuvastatin ibonakaliswe ukuba ine-anti-atherosclerotic, i-anti-inflammatory, i-antioxidant, i-plaque stabilizing, kunye ne-endothelial functionable properties.

I-Rosuvastatin iveliswa ngokubiliswa kwe-Aspergillus terreus okanye nge-chemical synthesis. Emva kokuba idliwe, i-metabolized ngokubanzi kwisibindi kwaye iguqulelwe kwii-metabolites ezahlukeneyo, kubandakanywa i-metabolites esebenzayo evimbela i-HMG-CoA reductase. Ichiza kunye ne-metabolites yalo ikhutshwe ngokuyinhloko kwi-feces, kunye nexabiso elincinci elikhutshwe kumchamo.